{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:00:36Z","timestamp":1785301236140,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2022\/09698\\u20130"],"award-info":[{"award-number":["2022\/09698\\u20130"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2022\/09699\\u20136"],"award-info":[{"award-number":["2022\/09699\\u20136"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2023\/08336\\u20130"],"award-info":[{"award-number":["2023\/08336\\u20130"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2018\/10052\\u20131"],"award-info":[{"award-number":["2018\/10052\\u20131"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2023\/15929\\u20137"],"award-info":[{"award-number":["2023\/15929\\u20137"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2022\/15126\\u20139"],"award-info":[{"award-number":["2022\/15126\\u20139"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2020\/03419\\u20136"],"award-info":[{"award-number":["2020\/03419\\u20136"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["312396\/2021\\u20130"],"award-info":[{"award-number":["312396\/2021\\u20130"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["552120\/2011\\u20131"],"award-info":[{"award-number":["552120\/2011\\u20131"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["304384\/2024\\u20130"],"award-info":[{"award-number":["304384\/2024\\u20130"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.tice.2025.103137","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:00:54Z","timestamp":1758020454000},"page":"103137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dual molecular axis of resistance and immunoresponsiveness to BCG in pT1 non-muscle invasive bladder cancer: Insights from HER-2, SERBP1, HABP4, and IFN-\u03b3 profiling"],"prefix":"10.1016","volume":"98","author":[{"given":"Jo\u00e3o Carlos Cardoso","family":"Alonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Mattoso","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Cardoso","family":"de Arruda Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"da Silva Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano Angelo","family":"Cintra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Guimaraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Luiz Lopes","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martim Corr\u00eaa","family":"Bottene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Felipe Prodocimo","family":"Lestingi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kobarg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5830-8938","authenticated-orcid":false,"given":"Wagner Jos\u00e9","family":"F\u00e1varo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tice.2025.103137_bib1","article-title":"The possible role furin and furin inhibitors in endometrial adenocarcinoma: a narrative review","volume":"7","author":"Al-Kuraishy","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"issue":"1","key":"10.1016\/j.tice.2025.103137_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur. Urol."},{"issue":"24","key":"10.1016\/j.tice.2025.103137_bib3","doi-asserted-by":"crossref","first-page":"17535","DOI":"10.3390\/ijms242417535","article-title":"OncoTherad\u00ae (MRB-CFI-1) nanoimmunotherapy: a promising strategy to treat bacillus Calmette-Guerin-Unresponsive Non-Muscle-Invasive bladder cancer: crosstalk among T-Cell CX3CR1, immune checkpoints, and the Toll-Like receptor 4 signaling pathway","volume":"24","author":"Alonso","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.tice.2025.103137_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tice.2025.103137_bib5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3892\/etm.2022.11640","article-title":"Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: a retrospective single-center experience","volume":"24","author":"Bai","year":"2022","journal-title":"Exp. Ther. Med"},{"issue":"21","key":"10.1016\/j.tice.2025.103137_bib6","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.3390\/cancers14215295","article-title":"The urothelial transcriptomic response to interferon gamma: implications for bladder cancer prognosis and immunotherapy","volume":"14","author":"Baker","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.tice.2025.103137_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00210-022-02325-0","article-title":"Commiphora myrrh: a phytochemical and pharmacological update","volume":"396","author":"Batiha","year":"2023","journal-title":"Naunyn Schmiede Arch. Pharm."},{"key":"10.1016\/j.tice.2025.103137_bib8","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3390\/cancers15051364","article-title":"A comprehensive analysis of immune response in patients with non-muscle-invasive bladder cancer","volume":"15","author":"Celada Luis","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.tice.2025.103137_bib9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J. Urol."},{"key":"10.1016\/j.tice.2025.103137_bib10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4331\/wjbc.v10.i3.44","article-title":"Complex interactomes and post-translational modifications of the regulatory proteins HABP4 and SERBP1 suggest pleiotropic cellular functions","volume":"10","author":"Colleti","year":"2019","journal-title":"World J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.tice.2025.103137_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J. Urol."},{"key":"10.1016\/j.tice.2025.103137_bib12","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1016\/j.bbamcr.2014.08.016","article-title":"Ki-1\/57 and CGI-55 ectopic expression impact cellular pathways involved in proliferation and stress response regulation","volume":"1843","author":"Costa","year":"2014","journal-title":"Biochim Biophys. Acta"},{"issue":"11","key":"10.1016\/j.tice.2025.103137_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12032-024-02533-z","article-title":"Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, tumor-infiltrating lymphocytes, and monoamine oxidases","volume":"41","author":"de Arruda Camargo","year":"2024","journal-title":"Med Oncol."},{"key":"10.1016\/j.tice.2025.103137_bib14","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The world health organization\/international society of urologic pathology consensus classification of urothelial (transitional) neoplasms of the urinary bladder","volume":"22","author":"Epstein","year":"1998","journal-title":"Am. J. Surg. Pathol."},{"issue":"16_","key":"10.1016\/j.tice.2025.103137_bib15","article-title":"Relevance of immune tumor microenvironment and its interaction with HABP4 and SERBP1 proteins in bladder cancer","volume":"42","author":"F\u00e1varo","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tice.2025.103137_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/srep36869","article-title":"Progesterone receptor membrane component 1 mediates progesterone-induced suppression of oocyte meiotic prophase I and primordial folliculogenesis","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.tice.2025.103137_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/bju.16298","article-title":"A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer","volume":"134","author":"Haas","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.tice.2025.103137_bib18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000528579","article-title":"Short-term and long-term morbidity after radical cystectomy in patients with NMIBC and comparison with MIBC: identifying risk factors for severe short-term complications","volume":"107","author":"Haas","year":"2023","journal-title":"Urol. Int"},{"key":"10.1016\/j.tice.2025.103137_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.tice.2025.103137_bib20","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"Jr; American society of clinical oncology. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Harris","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tice.2025.103137_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2013mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.tice.2025.103137_bib22","unstructured":"IARC-WHO Global Cancer Observatory. [(accessed on 15 July 2025)]. Available online: \u3008https:\/\/www.iarc.who.int\/cancer-type\/bladder-cancer\/\u3009."},{"key":"10.1016\/j.tice.2025.103137_bib23","doi-asserted-by":"crossref","unstructured":"Krajewski, W. , Zdrojowy, R. , Dembowski, J. , Poletajew, S. , Wr\u00f3bel, M. , \u0141uczak, M. , Tukiendorf, A. , Kolodziej, A. The optimal timing of restaging resection before introduction of bacillus Calmette-Guerin immunotherapy in patients with high-risk non-muscle-invasive bladder cancer. Urol Int 2019;102:60\u201368. https:\/\/doi.org\/10.1159\/000491642.","DOI":"10.1159\/000491642"},{"key":"10.1016\/j.tice.2025.103137_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdp488","article-title":"Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients","volume":"21","author":"La\u00e9","year":"2010","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.tice.2025.103137_bib25","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3892\/ijo.2017.4111","article-title":"SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB\/NF-\u03baB axis","volume":"51","author":"Ma","year":"2017","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.tice.2025.103137_bib26","first-page":"57","article-title":"Potential for HER-2\/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization","volume":"19","author":"Matsubara","year":"2008","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tice.2025.103137_bib27","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.18632\/oncotarget.27804","article-title":"Intracellular hyaluronic acid-binding protein 4 (HABP4): a candidate tumor suppressor in colorectal cancer","volume":"11","author":"Melo-Hanchuk","year":"2020","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.tice.2025.103137_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/0300060519895847","article-title":"HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy","volume":"48","author":"Moustakas","year":"2020","journal-title":"J. Int Med Res"},{"issue":"6","key":"10.1016\/j.tice.2025.103137_bib29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bju.15608","article-title":"Incidence of and mortality from bacille Calmette-Gu\u00e9rin (BCG) infections after BCG instillation therapy","volume":"129","author":"Nurminen","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.tice.2025.103137_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.tice.2025.103137_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International bladder cancer group consensus statement on clinical trial design for patients with bacillus Calmette-Gu\u00e9rin-exposed High-risk Non-muscle-invasive bladder cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.tice.2025.103137_bib32","first-page":"2985","article-title":"The potential role of MUC16 (CA125) biomarker in lung cancer: a magic biomarker but with adversity","volume":"12","author":"Saad","year":"2022","journal-title":"Diagn. (Basel)"},{"key":"10.1016\/j.tice.2025.103137_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2025.102783","article-title":"Clinical and immunohistochemical effects of OncoTherad (MRB-CFI-1) nanoimmunotherapy on SERBP1, HABP4, CD44 and Ki-67 in BCG-unresponsive non-muscle invasive bladder cancer","volume":"93","author":"Salmazo","year":"2025","journal-title":"Tissue Cell"},{"issue":"4","key":"10.1016\/j.tice.2025.103137_bib34","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.3390\/ijms24043720","article-title":"HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive role","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.tice.2025.103137_bib35","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.3390\/molecules26175163","article-title":"Impacting the remedial potential of nano Delivery-Based flavonoids for breast cancer treatment","volume":"26","author":"Sindhu","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.tice.2025.103137_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000356201","article-title":"HER2 expression and PI3K-Akt pathway alterations in gastric cancer","volume":"89","author":"Sukawa","year":"2014","journal-title":"Digestion"},{"key":"10.1016\/j.tice.2025.103137_bib37","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.tice.2025.103137_bib38","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.euo.2023.10.003","article-title":"Prognostic significance of HER2 expression in patients with bacillus Calmette-Gu\u00e9rin-exposed non-muscle-invasive bladder cancer","volume":"7","author":"Tan","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.tice.2025.103137_bib39","unstructured":"Tumor Pathology Committee of the Chinese Anti-Cancer Association, Expert Committee on Urothelial Carcinoma of the Chinese Society of Clinical Oncology. [Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China]. Zhonghua Zhong Liu Za Zhi 2021;43:1001\u20136. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20210809-00597."},{"key":"10.1016\/j.tice.2025.103137_bib40","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American society of clinical oncology; college of American pathologists. American society of clinical Oncology\/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tice.2025.103137_bib41","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical Oncology\/College of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.tice.2025.103137_bib42","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41556-019-0352-z","article-title":"HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity","volume":"21","author":"Wu","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.tice.2025.103137_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11255-014-0866-z","article-title":"Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis","volume":"47","author":"Zhao","year":"2015","journal-title":"Int Urol. Nephrol."}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816625004197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816625004197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:19:07Z","timestamp":1785298747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816625004197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":43,"alternative-id":["S0040816625004197"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2025.103137","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual molecular axis of resistance and immunoresponsiveness to BCG in pT1 non-muscle invasive bladder cancer: Insights from HER-2, SERBP1, HABP4, and IFN-\u03b3 profiling","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2025.103137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103137"}}